More than 20,000 Australians face being immediately shunted off their weight loss medications in June if the drug regulator proceeds with its telegraphed plans to ban replica versions of Ozempic and Mounjaro.
The pending move sets up a fight with online healthcare start-ups Eucalyptus and NIB’s Midnight Health, which offer the medications that are in short supply around the country.
Loading...
Nick Bonyhady is a technology writer for the Australian Financial Review, based in Sydney. He is a former technology editor, industrial relations and politics reporter at the Sydney Morning Herald and Age. Connect with Nick on Twitter. Email Nick at nick.bonyhady@afr.com
